Lung cancer is the most common cause of cancer death with limited survival. Most of the lung cancer cases are non-small cell variety, and most of the patients are in an advanced stage. After histopathological diagnosis, the next step is documenting the presence of actionable mutations like EGFR. When positive, EGFR portends sensitivity of the tumour to EGFR TKIs and a better prognosis. We report a case of advanced NSCLC with protracted survival of almost 10 years from the diagnosis of metastatic disease. The patient presented with progressions multiple times but was found non-compliant with Erlotinib. Compliance was reinforced every time, followed by the response on surveillance.
Key words: Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor, Erlotinib
|
